IP Library Patent Application 13488142
Patent Application
App. No. 13/488,142

DETERMINING THE CLINICAL SIGNIFICANCE OF VARIANT SEQUENCES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/488,142
Abstract

The present invention generally relates to determining the clinical significance of a variant nucleic acid sequence. The invention can involve sequencing a nucleic acid to generate at least one sequence read, identifying a variant sequence within the sequence read, determining the equivalent insertion/deletion region (EIR) of the variant sequence, identifying a functional region including at least a portion of the EIR, and associating the EIR with the identified functional region, thereby to determine the clinical significance of the variant.

Claims (15)

1 . A computer implemented method for determining the clinical significance of a variant sequence, the method comprising:

receiving at a computer sequence data representative of at least one sequence read that has been generated by sequencing a nucleic acid on a sequencer;

processing with the computer the sequence data by mapping the sequence read to a reference sequence in order to identify a variant sequence within the sequence read;

determining with the computer an equivalent insertion or deletion (indel) region of the variant sequence from the sequence data;

identifying with the computer a functional region comprising at least a portion of the equivalent indel region from the sequence data;

associating with the computer the equivalent indel region with the identified functional region; and

determining with the computer whether the equivalent indel region extends beyond the identified functional region, thereby determining a clinical significance of the variant sequence.

2 . The method of claim 1 , wherein the nucleic acid is selected from a group consisting of DNA, RNA, and cDNA.

3 - 4 . (canceled)

5 . The method of claim 1 , wherein the variant sequence comprises a true genetic mutation.

6 . The method of claim 5 , wherein the true genetic mutation is selected from an insertion or a deletion.

7 . The method of claim 5 , wherein the true genetic mutation is located in a tandem repeat.

8 . The method of claim 1 , wherein using the computer to determine from the sequence data an equivalent indel region of the variant sequence comprises selecting a functional region from a group consisting of: a gene, an exon, an intron, a splice site, a codon, a regulatory element, and a non-coding region.

9 . The method of claim 1 , wherein variant sequence is selected from a group consisting of: a splice site mutation, an in-frame mutation, a nonsense mutation, a mutation comprising an unknown nucleic acid base, and a frameshift mutation.

10 . (canceled)

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2023
From: PERCEPTIVE CREDIT HOLDINGS III, LP
To: INVITAE CORPORATION; GOOD START GENETICS, INC.; SINGULAR BIO, INC.; YOUSCRIPT, LLC
Reel/Frame 063282/0538 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE SCHEDULE A OF THE CONFIRMATORY ASSIGNMENT PREVIOUSLY RECORDED AT REEL: 056756 FRAME: 0884. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 11, 2021
From: GOOD START GENETICS, INC.
To: INVITAE CORPORATION
Reel/Frame 057772/0828 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: GOOD START GENETICS, INC.
To: INVITAE CORPORATION
Reel/Frame 056756/0884 →
PATENT SECURITY AGREEMENT Recorded Oct 2, 2020
From: INVITAE CORPORATION; GOOD START GENETICS, INC.; SINGULAR BIO, INC.; YOUSCRIPT, LLC
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 054234/0872 →
RELEASE OF SECURITY INTEREST Recorded Sep 11, 2019
From: INN SA LLC
To: INVITAE CORPORATION; GOOD START GENETICS, INC.; COMBIMATRIX CORPORATION
Reel/Frame 050454/0559 →
SECURITY INTEREST Recorded Nov 6, 2018
From: INVITAE CORPORATION; GOOD START GENETICS, INC.; COMBIMATRIX CORPORATION
To: INN SA LLC
Reel/Frame 047889/0836 →
RELEASE OF SECURITY INTEREST Recorded Feb 23, 2018
From: WESTERN ALLIANCE BANK
To: GOOD START GENETICS, INC.
Reel/Frame 045020/0296 →
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "B" L.P. FORMERLY CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: GOOD START GENETICS, INC.
Reel/Frame 043211/0658 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2013
From: KENNEDY, CALEB J., MR.; UMBARGER, MARK, MR.; PORRECA, GREGORY, MR.
To: GOOD START GENETICS, INC.
Reel/Frame 031306/0264 →
SECURITY AGREEMENT Recorded Apr 30, 2013
From: GOOD START GENETICS, INC.
To: BRIDGE BANK, NATIONAL ASSOCIATION
Reel/Frame 030315/0963 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Apr 25, 2013
From: GOOD START GENETICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 030295/0081 →